Literature DB >> 33768794

Patient with Down syndrome and relapsed acute lymphoblastic leukemia with sustained remission despite only partial R3 chemotherapy.

Zhongbo Hu1, Kristen A VanHeyst1, Jignesh Dalal1, Lisa Hackney1.   

Abstract

DS-ALL has a higher rate of relapse and treatment-related mortality. The newer immunotherapies are potentially better options. Relapsed ALL with positive MRD has a poor prognosis. Transient long-term remission after ALL relapse due to partial chemotherapy combined severe infection is rare.
© 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

Entities:  

Keywords:  ALL R3; Down syndrome; Relapsed acute lymphoblastic leukemia; remission

Year:  2021        PMID： 33768794      PMCID： PMC7981660          DOI： 10.1002/ccr3.3678

Source DB:  PubMed          Journal:  Clin Case Rep        ISSN： 2050-0904


  28 in total

1.  Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine.

Authors:  P Raanani; O Shpilberg; S Gillis; A Avigdor; I Hardan; M Berkowicz; O Sofer; I Lossos; A Chetrit; D Ben-Yehuda; I Ben-Bassat
Journal:  Leuk Res       Date:  1999-08       Impact factor: 3.156

Review 2.  Acute Lymphoblastic Leukemia in Children.

Authors:  Stephen P Hunger; Charles G Mullighan
Journal:  N Engl J Med       Date:  2015-10-15       Impact factor: 91.245

3.  Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group.

Authors:  Kelly W Maloney; William L Carroll; Andrew J Carroll; Meenakshi Devidas; Michael J Borowitz; Paul L Martin; Jeanette Pullen; James A Whitlock; Cheryl L Willman; Naomi J Winick; Bruce M Camitta; Stephen P Hunger
Journal:  Blood       Date:  2010-05-04       Impact factor: 22.113

Review 4.  Down syndrome and acute lymphoblastic leukaemia.

Authors:  James A Whitlock
Journal:  Br J Haematol       Date:  2006-10-10       Impact factor: 6.998

Review 5.  Treatment of pediatric acute lymphoblastic leukemia.

Authors:  Stacy L Cooper; Patrick A Brown
Journal:  Pediatr Clin North Am       Date:  2014-10-18       Impact factor: 3.278

6.  Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.

Authors:  Catriona Parker; Rachel Waters; Carly Leighton; Jeremy Hancock; Rosemary Sutton; Anthony V Moorman; Philip Ancliff; Mary Morgan; Ashish Masurekar; Nicholas Goulden; Nina Green; Tamas Révész; Philip Darbyshire; Sharon Love; Vaskar Saha
Journal:  Lancet       Date:  2010-12-03       Impact factor: 79.321

7.  Spontaneous Remission in an Older Patient with Relapsed FLT3 ITD Mutant AML.

Authors:  Pankit Vachhani; Jason H Mendler; Andrew Evans; George Deeb; Petr Starostik; Paul K Wallace; Eunice S Wang
Journal:  Case Rep Hematol       Date:  2016-12-29

8.  Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial.

Authors:  Catriona Parker; Shekhar Krishnan; Lina Hamadeh; Julie A E Irving; Roland P Kuiper; Tamas Révész; Peter Hoogerbrugge; Jeremy Hancock; Rosemary Sutton; Anthony V Moorman; Vaskar Saha
Journal:  Lancet Haematol       Date:  2019-02-27       Impact factor: 30.153

9.  Survival of adults with acute lymphoblastic leukemia in Germany and the United States.

Authors:  Dianne Pulte; Lina Jansen; Adam Gondos; Alexander Katalinic; Benjamin Barnes; Meike Ressing; Bernd Holleczek; Andrea Eberle; Hermann Brenner
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

10.  Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group.

Authors:  Trudy D Buitenkamp; Shai Izraeli; Martin Zimmermann; Erik Forestier; Nyla A Heerema; Marry M van den Heuvel-Eibrink; Rob Pieters; Carin M Korbijn; Lewis B Silverman; Kjeld Schmiegelow; Der-Cheng Liang; Keizo Horibe; Maurizio Arico; Andrea Biondi; Giuseppe Basso; Karin R Rabin; Martin Schrappe; Gunnar Cario; Georg Mann; Maria Morak; Renate Panzer-Grümayer; Veerle Mondelaers; Tim Lammens; Hélène Cavé; Batia Stark; Ithamar Ganmore; Anthony V Moorman; Ajay Vora; Stephen P Hunger; Ching-Hon Pui; Charles G Mullighan; Atsushi Manabe; Gabriele Escherich; Jerzy R Kowalczyk; James A Whitlock; C Michel Zwaan
Journal:  Blood       Date:  2013-11-12       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.